101 related articles for article (PubMed ID: 1543529)
1. Relationship between DNA-binding and biological activity of anilinoacridine derivatives containing the nucleic acid-binding unit SPKK.
Bailly F; Bailly C; Helbecque N; Pommery N; Colson P; Houssier C; Hénichart JP
Anticancer Drug Des; 1992 Feb; 7(1):83-100. PubMed ID: 1543529
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin.
Morier-Teissier E; Bailly C; Bernier JL; Houssin R; Helbecque N; Catteau JP; Colson P; Houssier C; Hénichart JP
Anticancer Drug Des; 1989 Jun; 4(1):37-52. PubMed ID: 2474298
[TBL] [Abstract][Full Text] [Related]
3. Interaction of two peptide-acridine conjugates containing the SPKK peptide motif with DNA and chromatin.
Flock S; Bailly F; Bailly C; Waring MJ; Hénichart JP; Colson P; Houssier C
J Biomol Struct Dyn; 1994 Feb; 11(4):881-900. PubMed ID: 8204221
[TBL] [Abstract][Full Text] [Related]
4. Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Denny WA; Baguley BC
Anticancer Drug Des; 1987 Aug; 2(1):61-70. PubMed ID: 3449085
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
Bacherikov VA; Chou TC; Dong HJ; Zhang X; Chen CH; Lin YW; Tsai TJ; Lee RZ; Liu LF; Su TL
Bioorg Med Chem; 2005 Jun; 13(12):3993-4006. PubMed ID: 15911312
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, DNA binding, and biological activity of a series of DNA minor-groove-binding intercalating drugs.
Bailly C; Pommery N; Houssin R; Henichart JP
J Pharm Sci; 1989 Nov; 78(11):910-7. PubMed ID: 2621573
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
Bacherikov VA; Chou TC; Dong HJ; Chen CH; Lin YW; Tsai TJ; Su TL
Bioorg Med Chem Lett; 2004 Sep; 14(18):4719-22. PubMed ID: 15324894
[TBL] [Abstract][Full Text] [Related]
8. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
Collyn-d'Hooghe M; Bernier JL; Henichart JP
Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
[TBL] [Abstract][Full Text] [Related]
10. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, DNA-cleaving properties and cytotoxicity of intercalating chelidamic acid derivatives.
Searcey M; McClean S; Madden B; McGown AT; Wakelin LP
Anticancer Drug Des; 1998 Dec; 13(8):837-55. PubMed ID: 10335263
[TBL] [Abstract][Full Text] [Related]
12. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution.
Lansiaux A; Tanious F; Mishal Z; Dassonneville L; Kumar A; Stephens CE; Hu Q; Wilson WD; Boykin DW; Bailly C
Cancer Res; 2002 Dec; 62(24):7219-29. PubMed ID: 12499262
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, DNA binding and cytotoxicity of isohelical DNA groove binding platinum complexes.
Wheate NJ; Webster LK; Brodie CR; Collins JG
Anticancer Drug Des; 2000 Oct; 15(5):313-22. PubMed ID: 11354307
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antitumor properties of nitracrine and amsacrine analogs.
Mazerska Z; Chołody M; Lukowicz J; Wysocka-Skrzela B; Ledóchowski A
Arzneimittelforschung; 1987 Nov; 37(11):1276-81. PubMed ID: 3326605
[TBL] [Abstract][Full Text] [Related]
17. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
18. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
19. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the in vivo and in vitro antileukemic activity of monosubstituted derivatives of 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Baguley BC; Cain BF
Mol Pharmacol; 1982 Sep; 22(2):486-92. PubMed ID: 6897281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
